Category: Europe

July 1, 2016 Off

AstraZeneca, LEO Pharma agree on Trolakinumab global rights deal

By Dino Mustafić

AstraZeneca has entered into an agreement with LEO Pharma A/S (LEO Pharma), a specialist in dermatology care, for the global licence to tralokinumab in skin diseases. As explained by AstraZeneca, Tralokinumab is a potential new medicine (an anti-IL-13 monoclonal antibody) that has completed a Phase IIb trial for the treatment of patients with atopic dermatitis, an inflammatory skin disease resulting in itchy, red, swollen and cracked skin.

April 8, 2016 Off

Allergan and Heptares team up for novel treatments in Alzheimer’s

By Dino Mustafić

Allergan and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation have entered into an agreement under which Allergan will license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer’s disease.